
Opinion|Videos|December 20, 2023
Enfortumab Vedotin and the Role of ADCs in Bladder Cancer
Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Enzalutamide plus talazoparib demonstrates clinical activity in mHSPC
4
Mina Fam, MD, highlights significance of tebipenem pivoxil approval for cUTI
5














